A decade’s effort to the understanding of in silico prediction of drug-induced liver injury - A perspective from the FDA Liver Toxicity Knowledge Base
This virtual meeting will include a perspective from Weida Tong (US FDA) and a discussion session.
A significant percentage of drugs that are withdrawn from the market or fail during the clinical trial stage of development do so because of liver toxicity. This is largely due to the poor prediction with the current preclinical models for human DILI. The goal of the FDA’s Liver Toxicity Knowledge Base (LTKB) is to address this challenge by data integration and in silico prediction of DILI. This presentation will discuss the current landscape of this area and the potential advancement using deep learning methodologies.